Evidence map›Paper›PMID 41621142›Full record

ArticleAtherosclerosis2026

Specific serotonin receptor antagonist reduces murine calcific atherosclerosis.

Andy Hon, Mimi Lu, Linda L Demer, Yin Tintut

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andy HonDepartments of Medicine, Los Angeles, CA, USA.
Mimi LuDepartments of Medicine, Los Angeles, CA, USA.
Linda L DemerDepartments of Medicine, Los Angeles, CA, USA; Bioengineering, Los Angeles, CA, USA; Physiology, Los Angeles, CA, USA.
Yin TintutDepartments of Medicine, Los Angeles, CA, USA; Physiology, Los Angeles, CA, USA; Orthopaedic Surgery, University of California, Los Angeles, CA, USA. Electronic address: ytintut@mednet.ucla.edu.

Funding

Role of intermittent activation of parathyroid hormone receptor in exercise-induced vascular calcificationR01HL151391 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2021 to 2024
$2.2M
Serotonin receptor contribution to inflammation-induced calcific aortic valve diseaseR01HL137647 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2019 to 2022
$1.6M
Mechanisms of intermittent parathyroid hormone effects on calcific aortic diseaseR01HL121019 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2015 to 2018
$1.5M
NHLBI NIH HHS R01 HL121019NHLBI NIH HHS R01 HL137647NHLBI NIH HHS R01 HL151391
6 · The paper itself

Abstract

High levels of peripheral serotonin, produced in the gut, are associated with increased cardiovascular disease risk and bone loss. We previously found that vascular smooth muscle and valvular cells express serotonin receptors, predominantly type 2A (HTR-2A) at baseline and type 2B (HTR-2B) upon TNF-a stimulation. Serotonin treatment augmented TNF-a-induced matrix calcification, whereas the inhibitor of gut serotonin, LP533401, blunted the initiation, but not the progression, of cardiovascular calcification in Apoe

Indexed as

Aortic DiseasesAtherosclerosisKetanserinReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2BSerotonin 5-HT2 Receptor AntagonistsSerotonin AntagonistsVascular CalcificationAnimalsBone DensityDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLMice, Knockout, ApoEKetanserinReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2BSerotonin 5-HT2 Receptor AntagonistsSerotonin AntagonistsAtherosclerosisCalcificationCTHyperlipidemiaSerotoninVascular

Identifiers

PMID41621142
PMCPMC13600254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.